OraSure Technologies, Inc. (FRA:EP3)
Germany · Delayed Price · Currency is EUR | Market Cap | 254.36M +40.7% |
| Revenue (ttm) | 98.39M -18.9% |
| Net Income | -43.00M |
| EPS | -0.62 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,140 |
| Open | 3.360 |
| Previous Close | 3.340 |
| Day's Range | 3.360 - 3.640 |
| 52-Week Range | 1.800 - 4.000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About OraSure Technologies
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid tes... [Read more]
Financial Performance
In 2025, OraSure Technologies's revenue was $115.02 million, a decrease of -38.10% compared to the previous year's $185.83 million. Losses were -$68.73 million, 252.5% more than in 2024.
Financial numbers in USD Financial StatementsNews
Craig-Hallum bullish on OraSure, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of OraSure (OSUR) with a Buy rating and $7 price target The firm believes Q3 is an inflection point that should be a catalyst…
OraSure initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of OraSure (OSUR) with a Buy rating and $7 price target
OraSure Technologies Earnings Call Transcript: Q2 2026
Q2 2026 revenue and gross margin exceeded guidance, driven by strong diagnostics and SMS growth, FDA clearances, and operational discipline. Delay in IntelliQuick CT/NG test FDA clearance does not impact 2026 growth or cash flow outlook. Cash position remains strong.
OraSure Technologies Earnings release: Q2 2026
OraSure Technologies released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
OraSure Technologies Quarterly report: Q2 2026
OraSure Technologies has published its Q2 2026 quarterly earnings report on August 5, 2026.
OraSure Announces Second Quarter 2026 Financial Results
BETHLEHEM, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its fi...
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, ...
OraSure receives FDA Emergency Use Authorization for OraQuick Ebola test
OraSure (OSUR) announced that it has received Emergency Use Authorization from the FDA for its second generation OraQuick Ebola 2.0 Rapid Antigen Test for use with whole blood in live…
OraSure Receives Emergency Use Authorization for Second Generation Ebola Test
The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. The rapid test detects the Bundibu...
OraSure announces FDA clearance of Colli-Pee Dx Urine Collection Kit
OraSure (OSUR) announced FDA clearance of its Colli-Pee Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche’s (RHHBY) tests for Chlamydia trachomatis, Neisseria gonorrhoea...
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today annou...
OraSure Technologies Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4% sequentially to $27.9 million, with gross margin expansion and strong diagnostics performance. Two FDA-cleared product launches are expected mid-year, supporting guidance for continued revenue growth and margin improvement.
OraSure Technologies Earnings release: Q1 2026
OraSure Technologies released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
OraSure Technologies Quarterly report: Q1 2026
OraSure Technologies has published its Q1 2026 quarterly earnings report on May 6, 2026.
OraSure Announces First Quarter 2026 Financial Results
BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its fin...
OraSure Technologies Proxy statement: Proxy filing
OraSure Technologies filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certai...
OraSure Technologies Proxy statement: Proxy filing
OraSure Technologies filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
OraSure Technologies Proxy statement: Proxy filing
OraSure Technologies filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
OraSure Technologies Proxy statement: Proxy filing
OraSure Technologies filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
OraSure Technologies Appoints John D. Bertrand to its Board of Directors
Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Techn...
OraSure Technologies Proxy statement: Proxy filing
OraSure Technologies filed a proxy statement on March 30, 2026, providing details for shareholder voting and corporate governance matters.
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All...
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technol...
Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says
Activist investor Altai Capital Management called on OraSure Technologies to explore a sale, saying the medical device maker could fetch double its current share price, according to a letter seen by...